Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals

Gary Wong, Jason S. Richardson, Todd Cutts, Xiangguo Qiu, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Experimental Ebola virus (EBOV) vaccines have previously been shown to protect animals against a high dose intramuscular (IM) challenge, which is seen as a stringent challenge model. However, the protective efficacy against other modes of infection, such as contact with infectious hosts, is unknown. Using a previously established EBOV transmission animal model, we evaluated the efficacy of an adenovirus-based EBOV vaccine given to guinea pigs (gps) 4 weeks before direct contact with untreated, infectious animals. Prior vaccination resulted in robust levels of EBOV-specific antibodies and conferred complete protection in gps. These results support the use of vaccines to prevent EBOV transmission between hosts.

Original languageEnglish (US)
Pages (from-to)17-19
Number of pages3
JournalAntiviral research
Volume116
DOIs
StatePublished - Apr 2015
Externally publishedYes

Keywords

  • Adenovirus
  • Ebola
  • Guinea pigs
  • Transmission
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint

Dive into the research topics of 'Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals'. Together they form a unique fingerprint.

Cite this